Cited 0 times in Scipus Cited Count

Hypertension as a risk factor for recurrent subretinal hemorrhage in polypoidal choroidal vasculopathy

DC Field Value Language
dc.contributor.authorChung, YR-
dc.contributor.authorSeo, EJ-
dc.contributor.authorKim, YH-
dc.contributor.authorYang, H-
dc.contributor.authorLee, K-
dc.date.accessioned2018-05-04T00:25:08Z-
dc.date.available2018-05-04T00:25:08Z-
dc.date.issued2016-
dc.identifier.issn0008-4182-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/14958-
dc.description.abstractOBJECTIVE: To investigate the relationship between hypertension and recurrent subretinal hemorrhage (SRH) in eyes with polypoidal choroidal vasculopathy (PCV). DESIGN: Retrospective, comparative case series. PARTICIPANTS: Thirty-eight eyes of 38 patients with PCV. METHODS: Ocular findings and clinical features were analyzed retrospectively in patients with PCV enrolled from January 2011 to December 2013. The patients were divided into 2 groups according to the presence of recurrent SRH after successful initial treatment (rebleeding vs nonrebleeding) and were subdivided into those with and without hypertension, based on history of hypertension, systolic blood pressure (SBP) >150 mm Hg. The relationship between hypertension and recurrent SRH was analyzed. RESULTS: Thirty-eight patients (38 eyes) were included in this analysis. High SBP or history of hypertension was significantly more frequent in the rebleeding group than in the nonrebleeding group (p = 0.014). Subgroup analysis showed that mean time until recurrent SRH was significantly shorter in the hypertensive group than in the nonhypertensive group (p = 0.025). The cumulative incidence of recurrent SRH at 2 years was 43% in the hypertensive group and 20% in the nonhypertensive group. Cox regression after adjustment for age showed that hypertension was associated with a 3.9-fold greater risk of recurrent SRH (p = 0.039). CONCLUSIONS: Recurrent SRH in patients with PCV was more common in hypertensive subjects. Undiagnosed hypertension should be considered when assessing the prognosis of patients with PCV.-
dc.language.isoen-
dc.subject.MESHAged-
dc.subject.MESHAngiogenesis Inhibitors-
dc.subject.MESHBevacizumab-
dc.subject.MESHBlood Pressure-
dc.subject.MESHChoroidal Neovascularization-
dc.subject.MESHFemale-
dc.subject.MESHFluorescein Angiography-
dc.subject.MESHHumans-
dc.subject.MESHHypertension-
dc.subject.MESHIncidence-
dc.subject.MESHIntravitreal Injections-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPhotochemotherapy-
dc.subject.MESHPolyps-
dc.subject.MESHProportional Hazards Models-
dc.subject.MESHRanibizumab-
dc.subject.MESHRecurrence-
dc.subject.MESHRetinal Hemorrhage-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHRisk Factors-
dc.subject.MESHVascular Endothelial Growth Factor A-
dc.subject.MESHVisual Acuity-
dc.titleHypertension as a risk factor for recurrent subretinal hemorrhage in polypoidal choroidal vasculopathy-
dc.typeArticle-
dc.identifier.pmid27769325-
dc.contributor.affiliatedAuthor정, 유리-
dc.contributor.affiliatedAuthor양, 홍석-
dc.contributor.affiliatedAuthor이, 기황-
dc.type.localJournal Papers-
dc.identifier.doi10.1016/j.jcjo.2016.02.012-
dc.citation.titleCanadian journal of ophthalmology. Journal canadien d'ophtalmologie-
dc.citation.volume51-
dc.citation.number5-
dc.citation.date2016-
dc.citation.startPage348-
dc.citation.endPage353-
dc.identifier.bibliographicCitationCanadian journal of ophthalmology. Journal canadien d'ophtalmologie, 51(5). : 348-353, 2016-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1715-3360-
dc.relation.journalidJ000084182-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Ophthalmology
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse